Tetrachlorodecaoxide API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Tetrachlorodecaoxide API 92047-76-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Tetrachlorodecaoxide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Tetrachlorodecaoxide
- Synonyms:
- TCDO , Tetrachlorodecaoxygen
- Cas Number:
- 92047-76-2
- DrugBank number:
- DB05389
- Unique Ingredient Identifier:
- 549BT7IE1Q
General Description:
Tetrachlorodecaoxide, identified by CAS number 92047-76-2, is a notable compound with significant therapeutic applications. WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the body digests foreign, potentially harmful substances. The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. The trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, cancer/tumors (unspecified), HIV infection, and inflammatory disorders (unspecified). Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Tetrachlorodecaoxide functions by: WF 10 is a 1: 10 dilution of tetrachlorodecaoxide (TCDO) formulated for intravenous injection. It was developed by Oxo Chemie in Switzerland as an adjunctive therapy to combination antiretroviral and opportunistic infection prophylaxis regimens in AIDS patients. WF 10 specifically targets macrophages. WF10 potentially modulates disease-related up-regulation of immune responses both in vitro and in vivo. Thus immune response is influenced in a way that inappropriate inflammatory reactions are downregulated. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Tetrachlorodecaoxide belongs to the class of inorganic compounds known as non-metal chlorites. These are inorganic non-metallic compounds containing a chlorite as its largest oxoanion, classified under the direct parent group Non-metal chlorites. This compound is a part of the Inorganic compounds, falling under the Homogeneous non-metal compounds superclass, and categorized within the Non-metal oxoanionic compounds class, specifically within the Non-metal chlorites subclass.
Categories:
Tetrachlorodecaoxide is categorized under the following therapeutic classes: Anions, Compounds used in a research, industrial, or household setting, Electrolytes, Elements, Gases, Halogens, Ions, Oxygen Compounds, Protective Agents, Radiation-Protective Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Tetrachlorodecaoxide is a type of Electrolytes
Electrolytes are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) that play a vital role in maintaining the balance of essential ions in the body. These ions include sodium, potassium, calcium, magnesium, and chloride, among others. Electrolytes are responsible for maintaining proper hydration, regulating nerve and muscle function, and supporting various physiological processes.
In the pharmaceutical industry, electrolytes are widely utilized in the formulation of oral rehydration solutions, intravenous fluids, and dialysis solutions. These medications are employed to treat conditions such as dehydration, electrolyte imbalances, and renal dysfunction.
The availability of high-quality electrolyte APIs is of utmost importance to ensure the efficacy and safety of these pharmaceutical products. Pharmaceutical manufacturers rely on reputable suppliers who adhere to stringent quality control measures and comply with Good Manufacturing Practices (GMP) to produce electrolyte APIs of consistent quality.
To meet regulatory requirements, electrolyte APIs undergo rigorous testing to confirm their identity, purity, and potency. This includes analysis using advanced techniques such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), and atomic absorption spectroscopy (AAS).
In conclusion, electrolytes are a vital category of pharmaceutical APIs used to maintain the balance of essential ions in the body. They are extensively employed in various medications aimed at treating dehydration, electrolyte imbalances, and renal dysfunction. Pharmaceutical manufacturers prioritize the use of high-quality electrolyte APIs to ensure the safety and efficacy of their products, and adherence to stringent regulatory standards is crucial in their production and testing processes.
